Identification of surrogate markers for determining drug activity using proteomics

McClelland, C. and Gullick, W. (2003) Identification of surrogate markers for determining drug activity using proteomics. Biochemical Society Transactions, 31 (6). pp. 1488-1490. ISSN 0300-5127.

Full text not available from this repository.

Abstract

In a high proportion of human carcinomas overexpression of the EGFR (epidermal growth factor receptor), a receptor tyrosine kinase, represents a potential target for cancer treatment. EGFR is induced to dimerize through ligand binding which activates the tyrosine kinase activity of the receptor. This catalyses the transfer of ATP's gamma-phosphate to hydroxyl groups of tyrosine residues on the receptor, creating binding sites that recruit downstream signalling proteins. New drugs, SMTKIs (small-molecule tyrosine kinase inhibitors), have been designed to inhibit the tyrosine kinase activity of the receptor, producing an anti-tumour effect. The development of surrogate markers to determine the drug activity of these new inhibitors would be of great benefit in drug evaluation and in the subsequent management of patient disease. This review describes current treatments of cancer using tyrosine kinase inhibitors and the use of proteomic analysis to identify possible markers of activity of these new drugs.

Item Type: Article
Subjects: Q Science > QD Chemistry > QD0241 Organic chemistry > QD0415 Biochemistry
Q Science > QH Natural history > QH0301 Biology (General)
Divisions: Faculty of Social and Applied Sciences > School of Human and Life Sciences
Depositing User: Dr Carol Margaret Trim
Date Deposited: 15 Jul 2015 16:07
Last Modified: 15 Jul 2015 16:07
URI: https://create.canterbury.ac.uk/id/eprint/13562

Actions (login required)

Update Item (CReaTE staff only) Update Item (CReaTE staff only)

Downloads

Downloads per month over past year

View more statistics

Share

Connect with us

Last edited: 29/06/2016 12:23:00